Why would a manufacturer choose to file a Statement instead of a Summary?

A manufacturer might prefer a Statement when it wants to avoid immediately publishing detailed technological characteristics or performance testing information that competitors could use, accepting the tradeoff of an ongoing 30-day response obligation instead; this choice is often strategic for high-profile, competitively sensitive, or controversial products, though most submitters still file Summaries because Statements create a compliance obligation that many companies underestimate.

Which option do most submitters choose in practice?

Both alternatives meet the disclosure requirement when prepared correctly. A Summary makes the required summary publicly available; a Statement creates an ongoing obligation to provide the specified redacted safety and effectiveness information on request.

All terms

RegulatoryRegulated Pathways Global Markets Startup Lifecycle

510(k) Summary vs 510(k) Statement

Two alternative disclosure mechanisms in a 510(k) submission, a Summary is public on FDA's website; a Statement promises to share Safety & Effectiveness info on request.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed June 20, 2026

Definition

A 510(k) Statement certifies that, following a substantial-equivalence determination, the submitter will provide all safety and effectiveness information within 30 days of any person’s request, including adverse information, excluding patient identifiers and trade-secret or confidential commercial information. A Summary meets 21 CFR 807.92 and is publicly available after clearance; do not promise same-day database posting.

What the regulation says

21 CFR 807.92 and 807.93 specify the Summary and Statement alternatives. Consult FDA’s database for the documents actually available for a particular clearance.

What this means in practice

Choice of Summary vs Statement has competitive and commercial implications. A well-written 510(k) Summary serves as marketing collateral, it's often the first technical document a hospital or competitor sees. A Statement provides less public visibility but creates an obligation to fulfill information requests within 30 days, which most companies underestimate. For high-profile or controversial products, the choice is often strategic.

Examples

Illustrative: A MedTech company developing a new surgical instrument chose to submit a 510(k) Summary to ensure their device's technical specifications and safety data were readily accessible to potential customers and clinicians on the FDA website.
Illustrative: Another manufacturer, launching an innovative diagnostic software, opted for a 510(k) Statement, preferring to control the dissemination of detailed safety and effectiveness information, which they would provide directly to individuals upon formal request.
Illustrative: During due diligence for a potential acquisition, an investor specifically reviewed the acquiring company's cleared devices by examining their publicly available 510(k) Summaries on the FDA's database to assess their market presence and regulatory compliance.

Common pitfalls

•Filing a Summary that is too thin, FDA expects substantial detail about indications, technological characteristics, performance testing, and substantial equivalence rationale.
•Filing a Statement and then being unable to respond to information requests within 30 days, failure constitutes a violation.
•Treating a 510(k) Summary as confidential or promising that FDA will publish it on the clearance date.

Frequently asked questions

Grouped by theme

Editor's picks

· Hand-selected related concepts

Regulatory

510(k) Premarket Notification(510(k))

FDA submission demonstrating a device is substantially equivalent to a legally marketed predicate.

Regulatory

Abbreviated 510(k)

510(k) variant that relies on FDA guidance, special controls, or recognized consensus standards.

Regulatory

Predicate Device

A legally marketed device used as the comparator in a 510(k) submission.

Regulatory

Special 510(k)(Special 510(k))

Streamlined 510(k) for modifications to a manufacturer's own legally marketed device.

More in Regulatory

· Same category

Regulatory

Substantial Equivalence(SE)

The legal standard a 510(k) device must meet versus a predicate.

Regulatory

Third-Party Review of 510(k)(3P 510(k))

Program in which FDA-accredited third parties conduct the initial 510(k) review for eligible device types.

Regulatory

513(g) Request for Information(513(g))

Formal mechanism to ask FDA whether a product is a device and, if so, its likely classification.

Regulatory

Accreditation Scheme for Conformity Assessment(ASCA)

FDA voluntary program in which accredited testing labs perform standards-based testing accepted with reduced FDA scrutiny.

Cited by

Where this term appears across MedTech Terms.

Ecosystems (3)

Latest in MedTech

Sources

4 sources

Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Official-source claim check: 2026-11-01

A summary and statement are alternative disclosure mechanisms; the statement covers a redacted duplicate of safety and effectiveness information, not merely a short summary.

Partial review: verified corrections are applied, but this is not a full accuracy certification. The last full review date is unchanged.

Remaining verification limits

Original merged record reviewed in full. Illustrative examples are hypothetical, not verified case histories. Evidence supports the specific propositions below, not an assertion that every linked page verifies all merged content.

Tier 1Binding law and standards· 2Tier 2Regulator guidance and consensus· 2

Link health: 3 verified 1 unchecked· last checked 2026-06-20

eCFR·2FDA·2

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Regulatory0 / 101

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Regulatory
Sources: 4
Updated: 6/20/2026

Compare with another term

Learn in 60 seconds

Two alternative disclosure mechanisms in a 510(k) submission, a Summary is public on FDA's website; a Statement promises to share Safety & Effectiveness info on request.

·Choice of Summary vs Statement has competitive and commercial implications.
·A well-written 510(k) Summary serves as marketing collateral, it's often the first technical document a hospital or competitor sees.
·A Statement provides less public visibility but creates an obligation to fulfill information requests within 30 days, which most companies underestimate.

Remember this

Watch out: Filing a Summary that is too thin, FDA expects substantial detail about indications, technological characteristics, performance testing, and substantial equivalence rationale.

Related terms

You may also need

Auto-suggested from Regulatory and shared keywords.

All Regulatory terms

From the Blue Goat network

Related resources and services on this topic.